Stock listing
NASDAQ:CMPX Compass Therapeutics, Inc. Stock
Home listing (NASDAQ) of Compass Therapeutics, Inc.
Follow Compass Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CMPX
$0.688 USD +0.077 (+12.6%)
Close on Nov 20, 2026
- Day range
- $0.641 – $0.730 USDNov 20, 2026
- Volume
- 1.82M sharesNov 20, 2026
- Market cap
- $123.9M USDAt the close on Nov 20, 2026 · price × 180.1M shares outstanding
- 52-week range
- $0.570 – $6.880 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.78M USDMedian day 2.52M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CMPX · Home | $0.688 USD | +0.077 (+12.6%) | 1,823,677 | $0.671 | $0.730 | $0.641 | $0.611 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CMPX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.688 | +0.077 | +12.6% | $0.671 | $0.730 | $0.641 | 1,823,677 | |
| $0.611 | +0.004 | +0.7% | $0.624 | $0.640 | $0.594 | 1,788,200 | |
| $0.607 | -0.055 | -8.3% | $0.644 | $0.662 | $0.570 | 2,903,203 | |
| $0.662 | -0.112 | -14.5% | $0.768 | $0.778 | $0.660 | 2,042,843 | |
| $0.774 | -0.046 | -5.6% | $0.830 | $0.830 | $0.751 | 1,549,519 | |
| $0.820 | -0.010 | -1.2% | $0.824 | $0.830 | $0.800 | 1,842,834 | |
| $0.830 | -0.008 | -0.9% | $0.853 | $0.855 | $0.810 | 1,524,280 | |
| $0.838 | +0.001 | +0.1% | $0.849 | $0.896 | $0.830 | 2,118,377 | |
| $0.837 | +0.078 | +10.3% | $0.797 | $0.845 | $0.772 | 2,249,171 | |
| $0.759 | +0.074 | +10.8% | $0.700 | $0.760 | $0.671 | 1,849,895 | |
| $0.685 | -0.078 | -10.2% | $0.764 | $0.771 | $0.685 | 2,592,374 | |
| $0.763 | +0.010 | +1.3% | $0.785 | $0.800 | $0.754 | 1,861,925 | |
| $0.753 | -0.014 | -1.9% | $0.783 | $0.792 | $0.744 | 1,617,548 | |
| $0.768 | -0.019 | -2.4% | $0.811 | $0.811 | $0.750 | 2,114,525 | |
| $0.787 | +0.030 | +4.0% | $0.756 | $0.797 | $0.740 | 2,918,232 | |
| $0.756 | -0.004 | -0.5% | $0.780 | $0.810 | $0.751 | 2,025,282 | |
| $0.760 | +0.013 | +1.7% | $0.745 | $0.775 | $0.730 | 1,796,676 | |
| $0.747 | +0.000 | 0.0% | $0.752 | $0.785 | $0.730 | 2,210,224 | |
| $0.747 | -0.014 | -1.8% | $0.750 | $0.793 | $0.741 | 2,231,672 | |
| $0.761 | -0.040 | -5.1% | $0.781 | $0.807 | $0.750 | 2,128,369 | |
| $0.802 | -0.013 | -1.6% | $0.813 | $0.841 | $0.780 | 2,173,546 | |
| $0.815 | -0.019 | -2.3% | $0.822 | $0.845 | $0.808 | 1,544,138 | |
| $0.833 | -0.002 | -0.2% | $0.833 | $0.868 | $0.822 | 1,883,132 | |
| $0.835 | -0.025 | -2.9% | $0.870 | $0.889 | $0.826 | 3,119,040 | |
| $0.860 | -0.037 | -4.1% | $0.900 | $0.909 | $0.860 | 2,038,934 | |
| $0.897 | +0.018 | +2.0% | $0.860 | $0.905 | $0.850 | 3,339,175 | |
| $0.879 | +0.022 | +2.6% | $0.831 | $0.882 | $0.822 | 4,969,084 | |
| $0.857 | -0.081 | -8.6% | $0.931 | $0.938 | $0.854 | 3,800,409 | |
| $0.938 | -0.055 | -5.6% | $0.990 | $0.990 | $0.920 | 4,436,731 | |
| $0.993 | +0.010 | +1.0% | $0.993 | $1.050 | $0.978 | 3,670,889 | |
| $0.983 | -0.037 | -3.6% | $1.010 | $1.010 | $0.957 | 7,042,690 | |
| $1.020 | +0.022 | +2.2% | $0.980 | $1.055 | $0.965 | 2,792,590 | |
| $0.998 | +0.037 | +3.9% | $0.990 | $1.020 | $0.940 | 7,286,326 | |
| $0.961 | +0.104 | +12.1% | $0.910 | $1.000 | $0.890 | 15,831,950 | |
| $0.857 | -0.044 | -4.9% | $0.940 | $0.980 | $0.829 | 20,754,221 | |
| $0.901 | -0.139 | -13.4% | $1.030 | $1.055 | $0.901 | 10,067,700 | |
| $1.040 | -0.060 | -5.5% | $1.100 | $1.100 | $1.020 | 5,656,969 | |
| $1.100 | -0.010 | -0.9% | $1.125 | $1.150 | $1.090 | 3,500,547 | |
| $1.110 | -0.020 | -1.8% | $1.150 | $1.150 | $1.100 | 3,704,884 | |
| $1.130 | -0.005 | -0.4% | $1.170 | $1.195 | $1.120 | 3,532,924 | |
| $1.135 | -0.035 | -3.0% | $1.170 | $1.170 | $1.100 | 4,539,648 | |
| $1.170 | -0.070 | -5.6% | $1.220 | $1.230 | $1.130 | 7,693,255 | |
| $1.240 | -0.580 | -31.9% | $1.250 | $1.440 | $1.150 | 27,202,789 | |
| $1.820 | -0.080 | -4.2% | $1.880 | $1.880 | $1.800 | 2,987,340 | |
| $1.900 | +0.050 | +2.7% | $1.860 | $1.900 | $1.810 | 8,210,036 | |
| $1.850 | +0.020 | +1.1% | $1.880 | $1.940 | $1.840 | 2,515,917 | |
| $1.830 | -0.020 | -1.1% | $1.870 | $1.895 | $1.800 | 2,242,999 | |
| $1.850 | -0.110 | -5.6% | $1.980 | $1.980 | $1.850 | 2,440,059 | |
| $1.960 | -0.040 | -2.0% | $2.025 | $2.040 | $1.960 | 2,278,976 | |
| $2.000 | -0.050 | -2.4% | $2.080 | $2.090 | $1.955 | 4,828,614 | |
| $2.050 | -0.130 | -6.0% | $2.170 | $2.170 | $2.040 | 2,541,061 | |
| $2.180 | -0.030 | -1.4% | $2.220 | $2.249 | $2.170 | 2,614,911 | |
| $2.210 | -0.170 | -7.1% | $2.320 | $2.325 | $2.200 | 2,428,040 | |
| $2.380 | +0.010 | +0.4% | $2.340 | $2.445 | $2.330 | 2,548,324 | |
| $2.370 | -0.060 | -2.5% | $2.440 | $2.440 | $2.345 | 2,559,952 | |
| $2.430 | +0.120 | +5.2% | $2.310 | $2.460 | $2.310 | 2,539,819 | |
| $2.310 | -0.080 | -3.3% | $2.370 | $2.395 | $2.290 | 1,512,903 | |
| $2.390 | -0.010 | -0.4% | $2.400 | $2.400 | $2.310 | 3,523,042 | |
| $2.400 | -0.120 | -4.8% | $2.510 | $2.510 | $2.400 | 2,567,637 | |
| $2.520 | +0.090 | +3.7% | $2.440 | $2.530 | $2.400 | 1,941,408 | |
| $2.430 | -0.100 | -4.0% | $2.510 | $2.520 | $2.410 | 1,445,009 | |
| $2.530 | +0.130 | +5.4% | $2.400 | $2.550 | $2.390 | 2,295,274 | |
| $2.400 | 0.000 | 0.0% | $2.420 | $2.430 | $2.320 | 974,876 | |
| $2.400 | +0.040 | +1.7% | $2.390 | $2.450 | $2.330 | 2,032,331 | |
| $2.360 | -0.120 | -4.8% | $2.420 | $2.455 | $2.310 | 2,179,350 |
- Ticker
- NASDAQ:CMPX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 45 slides
Latest news
Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update
Nov 9, 2026
Closed $0.837 (+10.3%) on Nov 9, 2026
Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
Nov 6, 2026
Closed $0.759 (+10.8%) on Nov 6, 2026
Compass Therapeutics to Participate in Upcoming November Investor Events
Nov 2, 2026
Closed $0.768 (-2.4%) on Nov 2, 2026
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
Oct 24, 2026
Closed $0.747 (-1.8%) on Oct 26, 2026
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 14, 2026
Closed $0.897 (+2.0%) on Oct 15, 2026
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Sep 22, 2026
Closed $1.24 (-31.9%) on Sep 22, 2026
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
Aug 6, 2026
Closed $1.99 (+5.3%) on Aug 6, 2026
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Jul 17, 2026
Closed $2.05 (-2.4%) on Jul 17, 2026
Compass Therapeutics to Participate in Upcoming June Investor Events
May 28, 2026
Closed $2.41 (+6.2%) on May 28, 2026
Compass Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 104 in all · newest Nov 9, 2026 · oldest 2021
- Calls
- 1 call with a replay · 1 with a transcript · latest Aug 11, 2025
- Decks
- 8 decks · latest September 2026
Where Compass Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CMPX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CMPX | BOATS | United States | USD |
Valuation
Price/book 0.9× against a median of 4.5×: 2nd lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$29.89M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.22
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Compass Therapeutics, Inc. · NASDAQ:CMPX | US$123.9M | −US$29.89M | n/a | n/a | n/a | 0.9× | n/a | 0.1× | 1.22 |
| Yoda Pharmaceuticals Inc. · TPEX:7829 | US$127.1M | US$94.39M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| IntoCell, Inc. · KRX:287840 | US$126.5M | US$108.8M | n/a | 45.9× | n/a | 8.7× | −295.9% | 0.0× | n/a |
| UnicoCell Biomed Co., Ltd. · TWSE:6794 | US$126.3M | US$106.5M | n/a | 117× | n/a | 5.1× | −381.5% | 0.1× | n/a |
| MacroGenics, Inc. · NASDAQ:MGNX | US$125.3M | −US$127.6M | n/a | −0.9× | n/a | 5.0× | −34.6% | 1.4× | 0.83 |
| PolyPid Ltd. · NASDAQ:PYPD | US$124.3M | US$119.3M | n/a | n/a | n/a | 23.1× | n/a | 0.3× | 0.93 |
| Humacyte, Inc. · NASDAQ:HUMA | US$123.7M | US$96.01M | n/a | 40.1× | n/a | 6.8× | n/a | 2.0× | 2.56 |
| Biomm SA · BMFBOVESPA:BIOM3 | US$122.6M | US$136.5M | 18.4× | 2.1× | 12.3× | 2.2× | 10.3% | 0.3× | n/a |
| Invivyd, Inc. · NASDAQ:IVVD | US$122.0M | US$3.86M | n/a | 0.1× | n/a | 0.8× | −214.8% | 0.1× | 2.06 |
| Satellos Bioscience Inc · TSX:MSCL | US$121.9M | US$69.25M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.49 |
| Alar Pharmaceuticals Inc · TPEX:6785 | US$121.0M | US$51.67M | n/a | 568× | n/a | 1.7× | n/a | 0.0× | n/a |
| Median of the others | US$124.0M | US$95.20M | 18.4× | 40.1× | 12.3× | 4.5× | −214.8% | 0.1× | 0.93 |
Forecasts
10 strong buy · 2 buy · 3 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.70 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.48 · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| James Boylan | CEO, Enavate Sciences |
| Thomas J. Schuetz | Chief Executive Officer, Compass Therapeutics |
| Barry Shin | Chief Financial Officer |
| Richard S. Lindahl | Executive Vice President, Chief Financial Officer and Treasurer, Emergent BioSolutions |
| Mary Ann Gray | President, Gray Strategic Advisors, LLC |
| Ellen V. Chiniara | Chief Legal Officer and Corporate Secretary, Kymera Therapeutics |
| Jonathan Anderman | Senior Vice President, General Counsel and Corporate Secretary |
| Ian Chia | Vice President of Business Development & Strategy |
| James Kranz | Vice President and Head of Chemistry Manufacturing and Controls |
| Karin Herrera | Senior Vice President and Head of Clinical Operations |
| Kris Sachsenmeier | Vice President of Translational Sciences |
| Neil Lerner | Senior Vice President, Chief Accounting Officer |
| Anna Gifford | Chief of Staff |
| Arjun Prasad | Chief Commercial Officer |
| Bing Gong | Chief Scientific Officer |
| Carl Gordon | Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC |
| ContactAnna Gifford | Chief of |
| Cynthia Sirard | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Carl Gordon | Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC |
| Ellen V. Chiniara | Chief Legal Officer and Corporate Secretary, Kymera Therapeutics |
| James Boylan | CEO, Enavate Sciences |
| Mary Ann Gray | President, Gray Strategic Advisors, LLC |
| Philip Ferneau | Managing Partner, Borealis Ventures |
| Richard S. Lindahl | Executive Vice President, Chief Financial Officer and Treasurer, Emergent BioSolutions |
| Thomas J. Schuetz | Chief Executive Officer, Compass Therapeutics |
Events
Calls
| Call | When | Status |
|---|---|---|
| Compass Therapeutics (NASDAQ:CMPX) Q2 2025 Earnings Call | Mon, Aug 11, 2025 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | +10.3% |
| Q2 2026 | Aug 6, 2026 · Before open | +5.3% |
| Q1 2026 | May 5, 2026 · Before open | +0.5% |
| Q4 2025 | Feb 27, 2026 | −1.7% |
| Q3 2025 | Nov 5, 2025 · Before open | +0.8% |
| Q2 2025 | Aug 11, 2025 · Before open | +23.7% |
| Q1 2025 | May 8, 2025 · Before open | +1.1% |
| Q4 2024 | Feb 28, 2025 | −6.5% |
| Q3 2024 | Nov 12, 2024 · Before open | −5.8% |
| Q2 2024 | Aug 12, 2024 · Before open | +3.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | −2.5% |
| Q4 2023 | Mar 21, 2024 · Before open | +5.7% |
| Q3 2023 | Nov 9, 2023 · Before open | −6.4% |
| Q2 2023 | Aug 3, 2023 · Before open | +1.5% |
| Q1 2023 | May 4, 2023 · Before open | −1.3% |
| Q4 2022 | Mar 15, 2023 · Before open | −1.1% |
| Q3 2022 | Nov 9, 2022 · Before open | −1.4% |
| Q2 2022 | Aug 1, 2022 · Before open | +1.5% |
| Q1 2022 | May 9, 2022 · Before open | −3.0% |
| Q4 2021 | Mar 18, 2022 · After close | +6.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 45 slides | September 2026 |
| Investor Presentation (July 2026) | Investor deck | 45 slides | Jul 1, 2026 |
| Investor Presentation (April 2026) | Investor deck | 16 slides | Apr 27, 2026 |
| Q2 2025 Earnings Presentation | Earnings | 18 slides | Aug 11, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 38 slides | Aug 11, 2025 |
| Investor Presentation (April 2025) | Investor deck | 10 slides | Apr 1, 2025 |
| Technical Presentation (January 2023) | Technical | 20 slides | Jan 23, 2023 |
| Investor Presentation (May 2022) | Investor deck | 36 slides | May 4, 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: Jefferies +2 Dealers: Jefferies (co-lead), Piper Sandler (co-lead), Guggenheim Securities (co-lead) Use of proceeds: Initial preparations for commercial readiness, research and clinical development of product candidates, and general corporate purposes | Aug 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 850.0K | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cost of revenue | 1.47M | 1.89M | 1.90M | 1.62M | 2.40M | 2.12M | 1.92M | |||
| Gross profit | -1.47M | 850.0K | -1.89M | -1.90M | -1.62M | -2.40M | -2.12M | -1.92M | ||
| Research and development | 56.0M | 42.3M | 38.1M | 30.0M | 20.3M | 14.9M | 22.4M | 27.1M | ||
| Selling, general and administrative | 16.9M | 15.1M | 12.2M | 11.7M | 10.9M | 12.9M | 11.6M | 11.2M | ||
| Operating income | -72.8M | -56.6M | -50.4M | -41.7M | -81.9M | -27.8M | -32.1K | -34.1M | -32.8K | -38.3M |
| Depreciation and amortization | 276.0K | 589.0K | 699.0K | 782.0K | 600.0K | 2.40M | 2.10M | 1.92M | ||
| EBITDA | -72.6M | -56.0M | -49.7M | -40.9M | -81.3M | -25.4M | -32.0M | -36.4M | ||
| Interest expense | 0 | 370.0K | 908.0K | 5.38K | 1.23M | 3.28K | 767.0K | |||
| Income before tax | -66.5M | -49.4M | -42.5M | -39.2M | -82.2M | -29.5M | -34.7M | -38.2M | ||
| Income tax | 0 | 0 | 0 | 0 | 0 | 32.0K | 91.0K | 103.0K | ||
| Net income | -66.5M | -49.4M | -42.5M | -39.2M | -82.2M | -29.5M | -37.5K | -34.7M | -36.0K | -38.3M |
| Earnings per share, basic | -0.42 | -0.36 | -0.33 | -0.37 | -1.31 | -0.96 | -0.01 | -5.19 | -0.01 | -7.66 |
| Earnings per share, diluted | -1.31 | -0.96 | -0.01 | -5.19 | -0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 30.6M | 43.5M | 24.2M | 34.9M | 144.5M | 47.1M | 3.75K | 25.3M | 4.87K | 57.5M |
| Short-term investments | 178.3M | 83.2M | 128.2M | 151.7M | 0 | |||||
| Receivables | 320.0K | |||||||||
| Current assets | 209.8M | 132.8M | 153.9M | 194.8M | 147.1M | 50.2M | 3.75K | 26.2M | 4.87K | 58.9M |
| Property, plant and equipment | 102.0K | 353.0K | 898.0K | 1.57M | 2.24M | 1.13M | 3.75M | 5.37M | ||
| Total assets | 219.6M | 140.4M | 156.9M | 199.6M | 153.8M | 51.9M | 3.75K | 30.4M | 4.87K | 64.6M |
| Accounts payable | 1.58M | 2.25M | 4.09M | 3.38M | 867.0K | 1.06M | 629.0K | 1.73M | ||
| Current liabilities | 14.0M | 8.87M | 7.80M | 16.2M | 10.6M | 10.1M | 111.8K | 9.82M | 75.5K | 8.46M |
| Long-term debt | 0 | 1.87M | 9.29M | 11.1M | ||||||
| Total debt | 9.83M | 6.63M | 1.73M | 2.94M | 0 | 9.33M | 14.9M | 14.8M | ||
| Total liabilities | 22.8M | 15.2M | 8.34M | 18.0M | 13.7M | 12.0M | 111.8K | 19.1M | 75.5K | 149.4M |
| Shareholders' equity | 196.8M | 125.2M | 148.5M | 181.6M | 140.1M | 39.9M | -124.8M | 11.3M | -95.3M | -84.8M |
| Shares outstanding | 178.3M | 137.8M | 127.7M | 126.3M | 100.8M | 51.2M | 5.00M | 7.03M | 5.00M | 5.00M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -49.1M | -44.9M | -40.6M | -34.1M | -19.7M | -26.8M | -32.1K | -31.7M | -32.8K | -33.7M |
| Capital spending | -25.0K | -44.0K | -30.0K | -212.0K | -1.57M | -106.0K | -466.0K | -2.02M | ||
| Free cash flow | -49.2M | -44.9M | -40.6M | -34.3M | -21.2M | -26.9M | -32.2M | -35.7M | ||
| Cash from investing | -93.3M | 46.8M | 27.0M | -151.2M | -1.77M | 38.0K | -466.0K | -2.02M | ||
| Cash from financing | 129.6M | 17.3M | 2.94M | 75.8M | 118.6M | 48.5M | 31.0K | 37.6K | 37.6K | 64.0M |
| Share buybacks | -159 | 75.8M | 128.0M | 54.2M | ||||||
| Change in cash | -12.8M | 19.3M | -10.7M | -109.6M | 97.2M | 21.8M | -1.12K | -32.2M | 4.87K | 28.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 22, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 8-K · Current report | Jul 1, 2026 | Current report | SEC |
| 8-K · Current report | Jun 22, 2026 | Current report | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 4/A · Change in ownership, amended | Apr 30, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 27, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jan 8, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 5, 2026 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Jan 5, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 2, 2026 | Other filings | SEC |
| DEL AM | Dec 31, 2025 | Other filings | SEC |
| S-3 · Registration statement | Dec 30, 2025 | Offer document | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 21, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 13, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Aug 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 12, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 11, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Apr 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 1, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 4, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2025 | Results | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 10, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | Sep 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 4, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 3, 2024 | Other filings | SEC |
| S-3 · Registration statement | Aug 30, 2024 | Offer document | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 3 · Initial statement of ownership | Aug 9, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Aug 2, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 17, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | May 28, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 28, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 25, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 22, 2024 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 1, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 9, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 5, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 27, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 3, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2023 | Results | SEC |
| 8-K · Current report | Jun 15, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 4, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Apr 27, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 24, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 24, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 24, 2023 | Management or board change | SEC |
| 10-K · Annual report | Mar 15, 2023 | Annual report | SEC |
| 4 · Change in ownership | Mar 10, 2023 | Insider trade | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
| 4 · Change in ownership | Feb 27, 2023 | Insider trade | SEC |
| 8-K · Current report | Feb 24, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Feb 15, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 10, 2023 | Insider trade | SEC |
| 8-K · Current report | Feb 10, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Feb 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 31, 2023 | Insider trade | SEC |
| 424B3 · Prospectus | Jan 24, 2023 | Offer document | SEC |
| 4 · Change in ownership | Jan 24, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jan 23, 2023 | Other filings | SEC |
| 8-K · Current report | Jan 19, 2023 | Current report | SEC |
| CORRESP · Letter to the SEC | Jan 19, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 17, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 13, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 7, 2022 | Other filings | SEC |
| S-3 · Registration statement | Dec 2, 2022 | Offer document | SEC |
| 8-K · Current report | Nov 29, 2022 | Management or board change | SEC |
| 4 · Change in ownership | Nov 25, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2022 | Insider trade | SEC |
This page holds 200 of 364 filings. Open Filings
Cap table
Built by 6ix from Compass Therapeutics, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 180,087,915
- Fully diluted
- 180,087,915
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 180,087,915 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 180,087,915 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Mark N Tompkins Other companies: Matternet Inc (Director · Since at least Sep 30, 2025); Deep Fission, Inc. (Director · Since at least Apr 20, 2022); Deep Isolation Nuclear, Inc. (Director · Since at least Apr 20, 2022); Guerrilla RF, Inc (Director · Mar 5, 2021 – Mar 5, 2021 · Past); Serve Robotics Inc. (Director · Mar 5, 2021 – Mar 5, 2021 · Past); Aeluma, Inc. (Director · Dec 1, 2020 – Dec 1, 2020 · Past); SmartKem, Inc. (Director · Aug 17, 2020 – Aug 17, 2020 · Past); Augmedix Inc (Director · May 13, 2019 – May 13, 2019 · Past) | Director · Jul 29, 2018 – Jul 29, 2018 · Past |
| Mary Ann Gray Other companies: BioAtla, Inc. (Director · Since at least Jun 16, 2022); Keros Therapeutics, Inc. (Director · Since at least Jun 1, 2022); RAPT Therapeutics Inc (Director · Since at least Mar 31, 2022); Palisade Bio, Inc. (Director · Jun 11, 2023 – Nov 21, 2023 · Past) | Director · Since at least Apr 26, 2022 |
| Miranda Toledano Other companies: Entera Bio Ltd. (Chief Executive Officer and Board Member · Since at least Jan 1, 2022); Journey Medical Corporation (Director · Since at least Nov 16, 2021); NexGel, Inc (Director · Sep 9, 2021 – Aug 17, 2023 · Past); Sorrento Therapeutics, Inc. (EVP-Corporate Development · Sep 16, 2016 – Sep 16, 2016 · Past) | Director · Jun 25, 2021 – Jun 25, 2021 · Past |
| Ellen V. Chiniara Other companies: Kymera Therapeutics, Inc. (Chief Legal Officer · Jan 3, 2023 – Mar 3, 2025 · Past); Alexion Pharmaceuticals Inc (EVP & Chief Legal Officer · Feb 12, 2018 – Jul 21, 2021 · Past); Alere Inc (GC, Chief Ethics Officer&Sec · Dec 31, 2010 – Oct 3, 2017 · Past) | Chief Legal Officer and Corporate Secretary, Kymera Therapeutics · Since at least Apr 26, 2022 |
| James Boylan Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Oct 10, 2024); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Immunome, Inc. (Director · Since at least Oct 2, 2023) | Director · Since at least Nov 4, 2022 |
| Richard S. Lindahl Other companies: Emergent BioSolutions Inc. (Executive Vice President · Since at least Mar 26, 2018); The Corporate Executive Board Company (Chief Financial Officer · Mar 27, 2013 – Apr 27, 2015 · Past); SPRINT Corp (Treasurer · Feb 7, 2006 – Aug 4, 2008 · Past) | Executive Vice President, Chief Financial Officer and Treasurer, Emergent BioSolutions · Since at least Apr 21, 2023 |
| Brett Kaplan Other companies: Climb Bio, Inc. (Chief Operating Officer · Aug 26, 2024 – Jan 13, 2025 · Past); Prevail Therapeutics Inc (Chief Financial Officer · Jun 19, 2019 – Jan 22, 2021 · Past) | Director · Sep 10, 2020 – Feb 18, 2022 · Past |
| Thomas J. Schuetz Other companies: Audentes Therapeutics Inc (Director · Jul 19, 2016 – Jan 15, 2020 · Past); Relypsa Inc (Director · Nov 14, 2013 – Sep 1, 2016 · Past) | Chief Executive Officer, Compass Therapeutics · Since at least Jun 17, 2020 |
| Barry Shin Other companies: Trevena, Inc. (Acting COO and CFO · Jun 25, 2019 – Oct 8, 2024 · Past) | Chief Financial Officer · Since at least Dec 9, 2024 |
| Cynthia Sirard Other companies: Cypherpunk Technologies Inc. (Chief Medical Officer · Apr 1, 2020 – Mar 28, 2025 · Past) | Chief Medical Officer · Since at least Jan 2, 2026 |
All 26 people
| Person | Seat |
|---|---|
| Vered Bisker-Leib Other companies: Ayala Pharmaceuticals Inc (Director · Aug 18, 2020 – Jan 19, 2023 · Past) | CHIEF EXECUTIVE OFFICER, Director · Jun 17, 2020 – Feb 8, 2024 · Past |
| Anna Gifford | Chief of Staff · Since at least Nov 2, 2026 |
| Arjun Prasad | Chief Commercial Officer · Since at least Jan 2, 2026 |
| Bing Gong | Chief Scientific Officer · Since at least Mar 5, 2026 |
| Carl Gordon | Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Nov 4, 2026 |
| ContactAnna Gifford | Chief of · Since at least Dec 17, 2025 |
| David M Wurzer | Director · Feb 8, 2023 – Feb 8, 2023 · Past |
| Ian Chia | Vice President of Business Development & Strategy · Since at least Nov 4, 2026 |
| James Kranz | Vice President and Head of Chemistry Manufacturing and Controls · Since at least Nov 4, 2026 |
| Jonathan Anderman | Senior Vice President, General Counsel and Corporate Secretary · Since at least Aug 1, 2024 |
| Julie Sunderland | Director · Jun 17, 2020 – Jun 19, 2020 · Past |
| Karin Herrera | Senior Vice President and Head of Clinical Operations · Since at least Nov 4, 2026 |
| Kris Sachsenmeier | Vice President of Translational Sciences · Since at least Nov 4, 2026 |
| Neil Lerner | Senior Vice President, Chief Accounting Officer · Since at least Apr 7, 2025 |
| Philip Ferneau | Managing Partner, Borealis Ventures · Since at least Jun 17, 2020 |
| Susan Kalled | Chief Scientific Officer · May 3, 2021 – Feb 18, 2022 · Past |
Log in to ask 6ix AI your own questions about Compass Therapeutics, Inc.